Inmune Bio Inc Stock Price, News & Analysis

INmune Bio, Inc. (NASDAQ: INMB) is set to host a conference call and webcast on May 5, 2022, at 4:30 PM ET to discuss first-quarter results ending March 31, 2022, and provide a corporate update. The call can be accessed via dial-in numbers and a live audio webcast link. The company develops therapies targeting the innate immune system, with key products in clinical trials for conditions such as cancer and Alzheimer's disease. Investors are advised that outcomes of ongoing clinical trials remain uncertain as they await FDA approvals.

Boca Raton, FL, April 25, 2022 – INmune Bio (NASDAQ: INMB) announced participation in the B. Riley Neuro & Ophthalmology Conference on April 28, 2022. RJ Tesi, MD, President and CEO, will engage in a fireside chat at 11:00 am ET. This invitation-only event caters to B. Riley Securities' institutional clients. INmune Bio is focused on using the innate immune system to develop treatments for diseases such as cancer and Alzheimer's, with products like INB03™ and XPro™ in clinical trials.

INmune Bio (NASDAQ: INMB) has initiated patient enrollment for a crucial six-month Phase 2 trial assessing XPro1595 in patients with mild Alzheimer's disease (AD). This multicenter, randomized, placebo-controlled study aims to evaluate cognitive function and improvement in biomarkers associated with neuroinflammation. Following positive results from the Phase 1 trial, which showed a reduction in neuroinflammation and improvements in neurorepair biomarkers, the company anticipates enrolling 201 patients across the U.S., Australia, and Canada.

INmune Bio (NASDAQ: INMB) has announced significant findings regarding its product INB03 for treating trastuzumab-resistant MUC4 HER2+ breast cancer. Data from animal models indicate that INB03 effectively decreases MUC4 expression, reversing resistance to trastuzumab and tyrosine kinase inhibitors while enhancing an active tumor microenvironment. This research was presented at the American Association of Cancer Research Annual Meeting. Previous studies reveal MUC4 expression correlates with poorer survival outcomes. INB03 is poised for further clinical testing.

INmune Bio (NASDAQ: INMB) presented significant findings regarding its NK cell therapy, INKmune™, during the NK Cells in Solid Tumors workshop at the Innate Killer Summit. Dr. Mark Lowdell, the CSO, emphasized INKmune™'s unique ability to enhance NK cell survival and function in hostile tumor environments by upregulating mitochondrial proteins and nutrient receptors. Clinical data suggests that INKmune-primed NK cells can persist in the body for over 15 weeks, raising the potential for synergistic use with adoptive NK therapies. The company continues to explore collaborations for future clinical trials.

INmune Bio, Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Lowdell, will lead a workshop at the 7th Innate Killer Summit in San Diego from March 30 to April 1, focusing on natural killer (NK) cells in treating solid tumors. The workshop aims to address challenges faced in NK cell therapies. Additionally, INmune will present case studies on INKmune™ showing promising results in three patients, including no side effects and improved disease outcomes. The company continues to advance its clinical trials targeting the innate immune system.

INmune Bio, Inc. (NASDAQ: INMB) recently presented at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's diseases held from March 15-20 in Barcelona, Spain. The company emphasized the growing importance of targeting neuroinflammation in Alzheimer's Disease (AD) treatments, particularly with its Xpro™ therapy. Notable findings include improved synaptic function indicators post-treatment and the use of white matter pathology as a biomarker for predicting AD progression. CEO R.J. Tesi highlighted the significance of these insights in advancing clinical trials and drug development strategies.

INmune Bio (NASDAQ: INMB) presented nine data pieces at the AD/PD^™ 2022 International Conference, held from March 15-20 in Barcelona, focusing on XPro™'s potential in treating Alzheimer’s Disease. This marks the first exposure for many EU and UK clinicians to INmune Bio’s approach targeting neuroinflammation. Key presentations include MRI measures from the Phase 1 trial and insights for Phase 2 trial design. The data emphasizes XPro™’s versatility and novel biomarkers being utilized in clinical strategies.

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced that its CEO, RJ Tesi, MD, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Dr. Tesi's corporate overview is scheduled for March 16, 2022, at 11:20am ET. Additionally, he will join a fireside chat at the 2022 Maxim Group Virtual Growth Conference on March 30, 2022, at 11:00am ET. INmune Bio is focused on treatments leveraging the immune system to combat diseases like cancer and Alzheimer's. Visit www.inmunebio.com for more information.